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Alternative methods are being developed to reduce, refine, and replace (3Rs) animals used in experiments, 
aimed at protecting animal welfare. The present study reports alternative tests which are based on the 
principles of the 3Rs and the efforts made to validate these tests. In Europe, several methodologies have 
already been implemented, such as tests of irritability, cell viability, and phototoxicity as well as in vitro 
mathematical models together with the use of in silico tools. This is a complex process that spans from 
development to regulatory approval and subsequent adoption by various official entities. Within this 
regulatory framework is REACH, the European Community Regulation for chemicals and their safe 
use. In Brazil, the BraCVAM (Brazilian Center for the Validation of Alternative Methods) was recently 
established to validate alternative methods and stimulate incorporation of new methodologies. A new 
vision of toxicology is emerging for the 21st century (Tox-21), and the subsequent changes are shaping 
a new paradigm.
Uniterms: Toxicology/alternative methods. Toxicological analysis/alternative methods. Toxicology/21st. 
century. Animals/use in experiments.
Métodos alternativos estão sendo desenvolvidos para a redução, o refinamento e a substituição (3R) 
do número de animais utilizados em experimentos, visando ao seu bem-estar. Esses testes alternativos 
baseiam-se no princípio dos 3R e esforços têm sido empregados para que sejam validados. Na Europa, 
diversas metodologias já foram implantadas tais como: testes de irritabilidade, testes de viabilidade 
celular, testes de fototoxicidade e modelos matemáticos in vitro, além do uso de ferramentas in silico. 
Esse é um processo complexo, que abrange desde o seu desenvolvimento até a aceitação regulatória 
e posterior adoção por diversas organizações oficiais. No contexto regulatório está o REACH, o 
Regulamento da Comunidade Européia, para produtos químicos e sua utilização segura. No Brasil, o 
BraCVAM (Centro Brasileiro de Validação de Métodos Alternativos) foi recentemente estabelecido 
para validação de métodos alternativos e estímulo à incorporação de novas metodologias. Uma nova 
visão de toxicologia vem surgindo para o século XXI (Tox-21) e as mudanças ocasionadas promoverão 
um novo paradigma.
Unitermos: Toxicologia/métodos alternativos. Análise toxicológica/métodos alternativos. Toxicologia/
século 21. Animais/uso em experimentos.
INTRODUCTION
The development of alternative methods for animal 
use, suggested by Russell and Burch (1959), has been 
prompted by concerns for animal welfare in laboratory 
experiments. some of the arguments raised by sectors 
of society have been based on the fact that alternative 
methods are able to replace the use of animals in research, 
a practice that is today considered obsolete. However, the 
idea is not to completely abolish the use of animals in 
research, as this could pose a risk to the advancement of 
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biological knowledge, testing, and development of new 
drugs, vaccines, and surgical methods (Morales, 2008; 
Rogiers, 2005).
Increased interest and daily advances within the 
scientific community has brought about the development 
of alternative methods in an attempt to reduce, replace, 
and refine the number of animals used in laboratory 
experiments, thus lowering the expenses incurred with 
the purchase of animals used in research (Hartung, 2011).
Currently, efforts are being made toward validating 
alternative tests. A reassessment of the use of animals in 
laboratory experiments is a worldwide trend, as evidenced 
in several countries by the founding of various institutions 
aimed at developing and validating new methods, 
regulations, and means by which to implement alternative 
tests in an attempt to legalize and standardize their use 
(Russel, Burch, 1959; Schechtman, 2002; GIBB, 2008; 
Balls, 1994). In this context, the knowledge pertaining to 
alternative tests and their use has been progressing.
The use of these alternative methods has become 
essential, given that they allow for a reduction in the 
number of animals used in laboratory experiments, for 
improvements in toxicological procedures that are less 
painful or stressful for the animals when undergoing tests, 
or for the replacement of tests on animals by in vitro and 
ex vivo tests or in silico systems (Kandárová, Letasiová, 
2011).
Since 2007, a new vision of toxicology for the 21st 
century (Tox-21 c) has been under debate (NRC) and is 
highly prevalent within the scientific community. These 
changes will most likely bring about a new paradigm in 
toxicology (Hartung, 2011).
Nonetheless, the enormous breakthrough that has 
occurred in this sector in recent years has mainly been 
due to government initiatives, in the form of government 
agencies responsible for the regulation and recognition 
of in vitro tests.
The aim of the present review was to address the 
main points concerning alternative methods, considering 
governmental initiatives and studies based on the 3Rs 
philosophy.
REGULATORY AGENCIES
Concerted efforts have been made in the search 
for new alternatives. In 1989, in Germany, the ZEBET 
(Zentrealstelle ErfassungBewertung von zur Ersatz 
und zum Erganzungsmethoden Tierversuch - National 
Center for the Documentation and Evaluation of 
Alternatives for Methods of Animal Experimentation) was 
created, whereas in 1993, the community established the 
European ECVAM (European Center for the Validation of 
Alternative Methods) (Spielmann, 2002).
In 1997, US government agencies formed the 
ICCVAM (Interagency Coordinating Center for the 
Validation of Alternative Methods). The ICCVAM consists 
of 15 research and regulatory agencies, among which 
number the Environmental Protection Agency (EPA), the 
Food and Drug Administration (FDA), and the Agency for 
Toxic Substances and Disease Registry (ATSDR). These 
organizations provide or use toxicological information 
for risk assessment processes. The Committee, through 
these federal agencies, seeks to coordinate discussions on 
the development, validation, and approval, in addition to 
national and international standardization, of toxicological 
tests (Iccvam, 1999, 2001, 2003).
In 2005, the Japanese government created the 
JaCVAM (Japanese Center for the Validation of Alternative 
Methods) while in 2011 BraCVAM (Brazilian Center for the 
Validation of Alternative Methods) was founded in Brazil. 
This center is the result of cooperative efforts between the 
Oswaldo Cruz Foundation (FIOCRUZ) and the Brazilian 
National Sanitation Agency (ANVISA, 2011).
In addition to the BraCVAM, the Ministry of 
Science, Technology, and Innovation (MCTI) established 
the National Network of Alternative Methods, which 
will be coordinated by the BraCVAM and INMETRO 
(National Institute of Quality Metrology, Standardization, 
and Industrialization). These efforts are aimed at bringing 
together groups of Brazilians working in this line of 
research. Once the BraCVAM has become fully functional, 
it is expected to develop research collaborations with 
similar centers worldwide (ANVISA, 2011).
Many previous initiatives will be exploited by 
BraCVAM, as one of its goals is to validate alternative 
methods that have been recognized throughout Europe 
and in the United States, as well as to encourage and 
incorporate new methodologies, through a process 
known as validation by capture. For Brazilian products 
in particular, such as antiophidic serum, it is intended 
to develop new forms of quality control which, if 
implemented, will also require the development of 
methodologies to validate these approaches within the 
context of national standards (Sustainable Planet, 2011).
Activities carried out by these governmental 
institutions focus on superseding the regulatory tests 
conducted on animals to identify toxic properties of 
chemical substances to which humans or the environment 
are exposed (Seidle, Stephens, 2009; Spielmann, 2002).
Currently, governmental initiatives are important to 
foster the development of the new methods and validate 
those already available.
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3R PHILOSOPHY
Alternative tests are part of the philosophy known as 
the “3R philosophy” (i.e. Replacement, Refinement, and 
Reduction) as regards animal testing, a fact cited in the first 
chapter of the document “Recognition and Alleviation of 
Pain in Laboratory Animals”, published by the National 
Research Council in 2009 (NCR, 2009).
After the introduction of several alternative methods, 
such as modeling (Q) SARs (Quantitative Structure-
Activity Relationship), the Organization for Economic 
Cooperation and Development (OECD) published reports 
and guides regarding validation (Cazarin et al., 2004). 
Some specific facts from these reports are noteworthy, 
such as replacing the OECD 401 guideline (acute toxicity) 
with the 420, 423, and 425 Guidelines, as well as the 
introduction of Guideline 428 (on dermal absorption) as 
an alternative to Guideline 427. These examples pertain 
to the refinement and reduction of animal experiments, 
especially as described in the document “OECD – 
Considerations on Animal Welfare in the Development 
of Test Guidelines”.
For cosmetic products, a current emerging reality, 
animal testing was set to be banned by 2003, following 
the 7th EU Directive on cosmetics (76/768/EEC) in 2003, 
animal testing was set to be banned by 2013. Since 
then, the ECVAM has been providing annual technical 
reports on the processes undertaken for the development, 
validation, and regulation of alternative methods in an 
attempt to meet the policy deadlines (ECVAM, 2010).
The 3R philosophy not only started this process, 
but has prompted many sectors of society, academy and 
government to develop potential methods for reducing the 
use of animals in research.
REGISTRATION, EVALUATION, AUTHORI-
ZATION, AND RESTRICTION OF CHEMICALS 
(REACH)
After the 7th EU Directive, the Registration, 
Evaluation, Authorization, and Restriction of Chemicals 
(REACH) regulation was established. REACH is the 
European Community Regulation on chemicals and 
their safe use. It deals with the Registration, Evaluation, 
Authorisation and Restriction of Chemical substances. 
The law was enacted on June, 1st 2007. The aim of 
REACH is to improve the protection of human health 
and the environment through more effective and earlier 
identification of the intrinsic properties of chemical 
substances. In parallel, REACH also aims to enhance 
innovation and competitiveness of the EU chemicals 
industry. The benefits of the REACH system will 
become apparent gradually, as more and more substances 
are phased into REACH (European Commission 
Environment, 2012).
With great scientific and technological innovations 
plus numerous new products, the market has grown rapidly. 
Thus, it is impossible to determine the toxicological profile 
of every product on the market, especially considering the 
current methods of toxicological evaluation. Nearly all of 
the provisions proposed by REACH are discussed within 
chemical industries worldwide, which boast some of the 
largest companies in the world (Brown, 2003).
The REACH Regulation places greater onus on 
industry to manage the risks from chemicals and to provide 
safety information on the substances. Manufacturers 
and importers are required to gather information on the 
properties of their chemical substances, which will allow 
their safe handling, and to register the information in a 
central database run by the European Chemicals Agency 
(ECHA) in Helsinki. The Agency acts as the central hub of 
the REACH system: it manages the databases necessary to 
operate the system, co-ordinates the in-depth evaluation of 
suspicious chemicals and is building up a public database 
in which consumers and professionals can find hazard 
information (Lilienblum, 2008).
Since 2004, the European Union has rejected the 
practice of using guinea pigs in producing cosmetics for the 
beauty market. During 2008 and 2009, ECVAM expanded 
its activities related to the development, validation, and 
optimization of alternative methods. Moreover, over the 
past two years, ECVAM has also become highly active in 
the regulation of alternative methods (ECVAM, 2010). 
Therefore, several international organizations support 
the use of alternative methods for toxicological tests, as 
well as extensive chemical and pharmaceutical support, 
because, in addition to the issue of ethics, the financial 
nature of this shift is quite favorable (Brown, 2003).
Concerned about this trend, some industries and 
universities in Brazil have invested in research and 
development aimed at abolishing animal testing, primarily 
in the production of cosmetics (ANVISA, 2011).
INITIATIVES FOR THE ADVANCEMENT OF 
ALTERNATIVE METHODS
To support this process, a report, commissioned 
by the European Commission, was recently published, 
providing a comprehensive overview of the alternative 
methods available to potentially replace animal testing 
in safety assessments of cosmetics, pharmaceuticals, 
and chemicals. The review includes five main areas: 
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toxicokinetics, dermal sensitization, repeated dose 
toxicity, carcinogenicity, and reproductive toxicity 
(Schmidt, 2009).
Hartung (2011), together with 16 experts from the 
US, Europe, and Japan, assessed this report. Some of 
these authors’ input may provide data that are suitable as a 
replacement for some animal studies in the future. Experts 
estimate that the replacement of animal experiments 
will be possible for aspects of skin sensitization and 
toxicokinetics in approximately 5-9 years. However, 
within 10 years, this replacement will be required for other 
areas as well.
Alternative methods present advantages, such as 
lower cost and time savings. Several learning centers 
in Brazil are using this methodology, however it is 
still undergoing evaluation. There are relatively few 
disadvantages of this alternative. Experts point out that, in 
some cases, the absence of interaction of a test substance 
with a living organism can impact results. However, in this 
case, with the advancement of scientific knowledge, this 
factor will soon be eliminated.
Some alternative methods, although not yet 
validated, are being developed and are supported at 
various research centers, such as the Committee on 
Alternative Tests from the Brazilian College of Animal 
Experimentation (Cobea) and the Pasteur Institute in São 
Paulo.
The use of in vitro Myography to replace lethality 
(LD50) tests using botulinum toxin (botox) is currently 
being performed on live animals in research conducted 
in the Department of Pharmacology, School of Medicine, 
the State University of Campinas (Bittencourt, 2012). 
Epidemiological and clinical studies, autopsies, and 
postmortem studies, as well as computer simulations and 
the use of mathematical models are also important tools 
in creating alternative methods.
Currently, all initiatives toward developing methods 
which can promote Replacement, Refinement, and 
Reduction, including working groups and Committees, 
are important to provide robust methods.
TWENTY-FIRST CENTURY TOXICOLOGY 
(TOX-21C)
In 2007, the National Research Council (NRC) 
published the report “Toxicity Testing in the 21st Century: 
A Vision and a Strategy” in an attempt to develop a long 
term vision for toxicity testing and outline a strategic plan 
to accomplish this. The new approach to toxicity testing 
demanded fewer animal studies and focused on in vitro 
methods for assessing risks that chemicals may pose to 
biological systems (Schmidt, 2009).
In 2008, a partnership was forged involving the 
National Toxicology Program (NTP), the National Institute 
of Health Chemical Genomics Center (NCGC), and the 
Environmental Protection Agency (EPA) to establish the 
Tox-21 program, aimed at promoting the advancement of 
toxicity tests. Each agency contributes with experience, 
resources, and tools to develop faster and more efficient 
approaches for predicting how chemicals can affect human 
health (Schmidt, 2009).
The Tox-21 proposes mapping a complete set of 
biochemical pathways involved in biological responses. 
Therefore, identification of the impairment from toxicity 
allows, the potential for human injury caused by chemicals 
to be inferred, i.e. the adverse effect or disease that would 
affect the human body if exposed to toxic substances 
(Collins et al., 2008).
Toxicity Testing in the 21st Century envisions a not-
so-distant future where virtually all routine toxicity testing 
will be conducted on human cells or cell lines in vitro by 
evaluating disturbances in cellular responses (Andersen, 
Krewski, 2009).
Currently, Tox-21 is a very important program 
to develop Toxicology as a science and a tool for 
evaluating the safety of substances because it addresses 
an issue which is weak in this area: mechanism of 
action. For example, it is very common to evaluate the 
structure-activity relationship (Pharmacology), yet very 
unusual to investigate the structure-toxicity relationship 
(Toxicology).
ALTERNATIVE TESTS
In vitro tests offer several advantages, including 
cont ro l led  tes t ing  condi t ions ;  a  h igh  leve l  of 
standardization; a reduction in variability between 
experiments; the absence of systemic effects; low cost 
testing; a small amount of material needed; a limited 
amount of toxic waste, cells, and human tissues used; as 
well as transgenic cells carrying human genes; and reduced 
animal testing.
However, the limitations of in vitro tests raise 
numerous questions, as discussed by Kandárová and 
Letasiová (2011). Questions include: How can the 
interactions between tissues and organs be tested? 
Can systemic effects be assessed? How can the 
pharmacokinetics be evaluated? How can the chronic 
effects be tested? In addition, there are also technical 
limitations involved: solubility and reaction to plastics. 
The following sections present some methods currently 
used for in vitro testing.
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Cell and tissue cultures
Cell and tissue cultures are also widely used in 
basic applied research. For example, studies into the 
effect of chemotherapy on the viability of cancer cells. 
These experiments are the basis for determining a drug’s 
potential to eliminate cancerous cells. Toxicity tests of 
some substances can also be carried out in cell cultures. 
Such assays support knowledge on whether or not a newly 
discovered drug or substance is toxic to cells in the human 
body (Wilmes et al., 2011).
Cells in culture are easy to handle and observe from 
microscopic, biochemical, and molecular viewpoints after 
the addition of substances within which these cells are 
cultured. However, this same substance tested on cells 
must be previously studied for the cells’ behavior when 
applied to a living organism (in experimental animals, 
especially mammals), given that, in vivo, many factors 
can interfere with the body’s own responses.
Nevertheless, prior in vitro studies have helped 
toward reducing the number of animals used in research. 
One concrete example of the use of human tissues in 
research is the pituitary gland. Growth hormones were 
extracted from the glands of deceased donors to be 
used in the treatment of children with impairments in 
the production of this hormone. This practice fell into 
disuse after finding contamination of some children with 
infectious diseases stemming from the donor (Jung et al., 
2009).
Bioengineering, using the bacterium Escherichia 
coli provides more efficient production of this hormone 
without the risk of contamination from donors. Moreover, 
tissues collected from breast biopsies can be used to study 
the development of cancer within the organ. Likewise, 
cells derived from tissues of other organs can be used for 
many different scientific purposes (Feist, Palsson, 2008).
Toxicity tests
Cell Viability Test
Cell viability tests consist of substances added 
to the culture mediums of specific cells in which some 
parameters of viability (or damage their membranes at 
their junction) are tested (Morales, 2008). Cell cultures 
drawn from different tissues can be used, and toxicity tests 
of various substances may be performed. Cell viability and 
damage to its structure are measures used in the analysis of 
specific parameters, such as toxicity. During development 
and reproduction, the toxicity test can be performed in 
chicken embryos, fish, and amphibians. This technique 
has proven to be very important (Blanton, 2007).
Recommendations from the OECD to reduce the use 
of animals are listed under guideline number 129/2009 – 
Guidance document on using cytotoxicity tests to estimate 
starting doses for acute oral systemic toxicity tests. This 
document describes the methods needed to determine the 
in vitro cytotoxicity of basal substances using neutral red 
uptake (NRU) and in vitro data to determine starting doses 
for oral toxicity in vivo.
A dose-response test is performed to determine 
the NRU concentration, which is reduced by 50% when 
compared to the controls (e.g., IC50). The IC50 value is 
used in a linear regression equation to estimate the value 
of LD50 by the oral route, which is then used to determine 
an initial dose for acute oral toxicity tests using rats.
The use of NRU in an approach to determine the 
starting dose for acute oral doses can reduce the number 
of animals needed for tests and substances needed to 
determine toxicity. To calculate the initial doses, in 
vitro data should be considered along with all other 
quantitative data and information, such as structure-
activity relationship (QSAR), the LD50 of related 
substances, and other data necessary to estimate the dose 
which most closely resembles to the real value of LD50.
Tests for ocular irritability
In the past, tests on substances that cause irritability 
were commonly performed by applying the substance 
directly on the cornea of rabbits (Draize test) (Draize et 
al., 1944). Several tests have been developed to replace 
this practice; some are indicated below (Bradlaw, Wilcox, 
1997).
Hen’s egg test on the chorioallantoic membrane 
HET-CAM: using fertilized chicken eggs to assess 
irritability of the chorioallantoic membrane, which 
contains a large number of blood vessels (Luepke, 1985).
Hemolysis test or Red Blood Cell (RBC): evaluates 
the phenomena of hemolysis and protein denaturation, 
resulting from the action of the test substance (Pape et 
al., 1987).
Bovine corneal opacity and permeability (BCOP). 
This method has been fully validated by international 
bodies (OECD guideline 437, 2009). The BCOP assay was 
developed as an alternative to the ocular dermal irritation 
test in rabbits (Draize) (Iccvam, 2003; Gibbs, 1985).
Isolated rabbit or chicken eye test: eyes isolated from 
dead animals (which were discarded) are tested for edema 
and corneal opacity, as well as retention of fluorescence, 
after exposure to the test substance (Morales, 2008).
Phototoxicity
The OECD also recommends testing Phototoxicity 
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in vitro (Guideline 432, 2004). This protocol is used to 
identify the phototoxic potential induced by chemicals 
after exposure to light. The test is evaluated by the relative 
reduction in cell viability when exposed to chemicals, in 
the presence versus absence of light. Substances identified 
in this test are likely to be phototoxic in vivo after systemic 
application and distribution on skin or topical application. 
The in vitro 3T3 NRU phototoxicity test was shown to be 
predictive of acute phototoxicity effects in animals and 
humans in vivo.
Mathematical models
Mathematical models can contribute to experimental 
work by defining variables and testing theories, reducing 
the cost of these experiments and rendering them more 
effective. One example is, the use mathematical models of 
the protein structure to, predict its physical and chemical 
properties (Ritchey, 2012).
 Tests on irritability could benefit from these 
studies; however, despite contributing toward decreasing 
the number of animals used, this methodology does not 
preclude final tests on animals or biological substitutes 
(e.g. fertilized egg chicken cell culture). It is always 
important to remember that computers process and store 
existing knowledge, much of which was acquired through 
the use of research on animals (Morales, 2008).
In silico
The advantages of in silico tools are unquestionably 
costs, standardization, and minimal equipment needs. 
These tools can also be easily integrated with other tools in 
integrated testing strategies. The limited public availability 
of these data, the lack of homogeneity of data sets, and 
selection bias of the data provided may well compromise 
modeling (Hartung, 2011). The application of molecular 
biology contributes to scientific breakthroughs in this line, 
including contributing to the assessment of health risks 
caused by potentially toxic chemicals (Gibb, 2008).
FINAL CONSIDERATIONS
The evaluation of substance toxicity has seen 
remarkable progress mainly, due to the regulatory 
agencies, such as ECVAM and ICCVAM. Thus, we hope 
BRACVAM can play an important role in this context. 
Currently, recognition by governments of the need to 
fost the development of 3R philosophy has been critical 
to this process, as has Tox 21, which aims to promote the 
TABLE I - Characteristics of in vitro assays
Assay General description Method of applying test material
Neutral Red Uptake
Target cells (primary or continuous; fibroblasts 
or epithelial-like) are grown in submerged 
monolayer culture
Generally increasing dilutions of test material are 
added to growth medium until a predetermined 
end point (generally cytotoxicity) is reached. e.g. 
raw material, topical product
BCOP
Living bovine corneas are treated with 
test material and changes in opacity and 
permeability are measured by instruments.
Test materials are applied neat or at in-use 
concentrations directly to the epithelial surface 
of the cornea. e.g. products used in the area of the 
eyes, shampoos, conditioners. 
Het-CAM Chorioallantoic membrane of a chicken egg is treated
Test materials are applied neat or at in-use 
concentrations directly to the membrane and 
damage to the membrane is recorded. e.g. 
products used in the area of the eyes, shampoos, 
conditioners
Red Blood Cell (RBC) Red blood cells are exposed to test material
Dilutions of test material used; lysis (release of 
hemoglobin) and hemoglobin denaturation are 
monitored. e.g. surfactants used in shampoos and 
liquid soaps
Phototoxicity
The test evaluates photo-cytotoxicity by the 
relative reduction in viability of cells exposed 
to the chemical in the presence versus absence 
of light.
This test is used to identify the phototoxic 
potential of a test substance induced by the 
excited chemical after exposure to light. Dilutions 
of test material are used. e.g. raw material, topical 
product.
Alternative methods in toxicity testing: the current approach 61
advancement of toxicity. These initiatives are in response 
to new demand, such as REACH, which aims to identify 
the intrinsic and toxicological properties of substances. 
Hence, the need to develop methods for evaluating the 
safety of substances has become an important issue. 
Therefore, several alternative tests are being developed 
and used as tools for preliminary assessments, such 
as physicochemical properties, structure-activity 
relationships, and the use of computer models, as well as 
in vitro and ex vivo tests. In addition, many working groups 
have been striving to debate new alternative methods. 
While alternative methods do help to reduce the number of 
animals required for drug research, there is no way they can 
completely eliminate the need for animals in preclinical 
studies at the present time. However, many of these in 
vitro tests are still unable to reliably predict toxicity in 
vivo. Based on this view and the trend toward international 
standardization, both the validation and implementation 
of alternative methods require the involvement of several 
regulatory agencies, which must assume the responsibility 
for guiding the process of developing new methodologies.
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